Entrada Therapeutics Inc. (TRDA)
8.79
0.03 (0.34%)
At close: Apr 02, 2025, 3:59 PM
9.15
4.04%
After-hours: Apr 02, 2025, 06:58 PM EDT
0.34% (1D)
| Bid | 8.26 |
| Market Cap | 330.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 1.68 |
| PE Ratio (ttm) | 5.24 |
| Forward PE | -4.34 |
| Analyst | Buy |
| Ask | 9.5 |
| Volume | 128,161 |
| Avg. Volume (20D) | 116,050 |
| Open | 8.64 |
| Previous Close | 8.76 |
| Day's Range | 8.63 - 8.87 |
| 52-Week Range | 8.63 - 21.79 |
| Beta | -0.14 |
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 183
Stock Exchange NASDAQ
Ticker Symbol TRDA
Website https://www.entradatx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 218.36% from the latest price.
Stock ForecastsNext Earnings Release
Entrada Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+11.26%
Entrada Therapeutics shares are trading higher. Th...
Unlock content with
Pro Subscription
